Inmune Bio, INC 8-K filings

INmune Bio announced the receipt of approximately $4.6 million in research and development cash rebates from Australia and the United Kingdom, strengthening its financial position and extending its cash runway.

INmune Bio Inc. has entered into agreements to extend the maturity date of certain outstanding warrants and secure cash through their partial exercise at a reduced price.

INmune Bio Inc. shareholders approved an increase in the number of shares available under the 2021 Stock Incentive Plan and implemented an evergreen provision.

INmune Bio announced statistically significant results from exploratory MRI imaging analyses in its Phase 2 MINDFuL trial of XPro for early Alzheimer's disease, showing a treatment effect on white matter.

INmune Bio announced its lead drug candidate, XPro (pegipanermin), has received FDA Fast Track designation for the treatment of early Alzheimer's disease.

INmune Bio Inc. and Anthony Nolan have entered into an amended and restated Material Transfer and License Agreement to secure long-term supply of umbilical cord tissue for INmune Bio's CORDStrom platform.

INmune Bio Inc. details significant progress in its CORDStrom program for RDEB and XPro1595 for Alzheimer's, including positive Phase 2 data and regulatory alignment for Phase 3.

INmune Bio announced FDA alignment for XPro1595 to advance to a registrational study for early Alzheimer's disease, with a webinar scheduled to detail the strategy.

INmune Bio will host a webinar on February 26, 2026, to present new Phase III clinical data for CORDStrom in treating recessive dystrophic epidermolysis bullosa (RDEB).

INmune Bio announced significant regulatory progress for its CORDStrom RDEB treatment in the UK and XPro1595 for early Alzheimer's Disease with the FDA.

INmune Bio Inc. issued a shareholder letter detailing 2025 clinical milestones and strategic initiatives for 2026, focusing on CORDStrom and XPro programs.

INmune Bio Inc. amended 1.35 million outstanding warrants, reducing the exercise price to $1.95 and extending their term to June 30, 2026, in exchange for $67,416.

INmune Bio Inc. has entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell up to $65 million of its common stock through an at-the-market offering.

INmune Bio Inc. has terminated its At-The-Market Sales Agreement with RBC Capital Markets and BTIG, effective December 19, 2025, after raising approximately $10.5 million.

INmune Bio Inc. has amended its Rights Agreement, extending the Final Expiration Date to December 31, 2026, with provisions for automatic annual renewals.

INmune Bio announced new neuroimaging data from its Phase 2 Alzheimer's trial showing slowed neurodegeneration and highlighted a peer-reviewed study supporting its CORDStrom platform.

INmune Bio Inc. filed an 8-K to correct errors in the employment agreements for its President and CEO, David J. Moss, and CFO, Cory Ellspermann, regarding base salaries and stock option grants.

INmune Bio Inc. announced new employment agreements for its CEO, CFO, and CSO, detailing compensation, equity grants, and severance provisions.

Shareholders approve a one-time option repricing to $1.50 and the company schedules two Alzheimer’s presentations at CTAD 2025.

INmune Bio Inc. provides an investor presentation detailing late-stage clinical programs for Alzheimer's disease and a rare pediatric inflammatory disease, highlighting regulatory milestones and positive Phase 2 data.

INmune Bio Inc. announced its third quarter 2025 financial results, reporting a reduced net loss and significant progress across its CORDStrom, DN-TNF (XPro), and INKmune platforms.

INmune Bio Inc. announced it will host a conference call on October 30, 2025, to discuss its third-quarter 2025 financial results and provide a corporate update.

INmune Bio's CEO, David Moss, will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit on October 22, 2025, discussing the company's CORDStrom platform.

INmune Bio submitted its Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer's disease to npj Dementia, showing promise in a specific patient subgroup despite not meeting the primary endpoint in the overall population.

INmune Bio announced its second quarter 2025 financial results, reported positive Phase I/II INKmune trial data, and provided updates on its XPro and CORDStrom platforms.

INmune Bio announced detailed findings from its Phase 2 MINDFuL trial for XPro in early-stage Alzheimer's disease, revealing the primary endpoint was not met in the overall population but showing consistent beneficial signals in a pre-specified enriched patient subgroup.

INmune Bio announced additional analyses from its Phase 2 MINDFuL trial of XPro for Alzheimer's disease will be presented at the Alzheimers Association International Conference, revealing consistent benefits in a specific patient subpopulation despite not meeting the primary endpoint in the overall group.

INmune Bio Inc., a clinical-stage biotechnology company, has successfully closed a registered direct offering, raising approximately $18.9 million in gross proceeds through the sale of 3 million common shares at $6.30 per share, intended for working capital and general corporate purposes.

INmune Bio announced topline Phase 2 MINDFuL trial results for XPro in early Alzheimer's disease, showing benefits in a predefined inflammatory subpopulation despite not meeting the primary endpoint in the broader cohort, and plans to seek Breakthrough Therapy Designation.

INmune Bio Inc. announced it will host a conference call on June 30, 2025, to present top-line results from its Phase 2 MINDFuL trial for early Alzheimer's disease.